Literature DB >> 8826952

Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck.

J Rubin Grandis1, M F Melhem, E L Barnes, D J Tweardy.   

Abstract

BACKGROUND: Transforming growth factor-alpha (TGF-alpha) and epidermal growth factor receptor (EGFR) mRNA are up-regulated in squamous cell carcinoma of the head and neck (SCCHN) tissues.
METHODS: Immunohistochemical staining with monoclonal antibodies to TGF-alpha and EGFR was undertaken to identify the cellular origin in tissue obtained from cancer patients and controls and to determine the correlation between mRNA expression levels and two methods of immunohistochemical evaluation.
RESULTS: TGF-alpha protein staining occurred in the suprabasal layers and spared the basal layer of normal controls. Conversely, in histologically normal mucosa from SCCHN patients, TGF-alpha was present throughout the epithelium, including the basal layer. EGFR staining was negligible in normal mucosa from control patients without cancer and relatively increased in SCCHN tissues. Increasing staining intensity was correlated with worsening dysplasia and closer proximity to the tumor. Using computerized image analysis to quantify the intensity of immunostaining, the mean optical density (MOD) of TGF-alpha staining in histologically normal mucosa (P = 0.049) and tumors (P = 0.005) from SCCHN patients was significantly higher than in control normal mucosa from noncancer patients (1.9- and 1.7-fold, respectively). EGFR MOD was also greater in the histologically normal mucosa (P = 0.009) and tumors (P = 0.006) from SCCHN patients than in control normal mucosa (1.8- and 1.9-fold, respectively). For both TGF-alpha (P = 0.668) and EGFR (P = 0.116), the MOD was similar for both tumor and histologically normal mucosa from SCCHN patients.
CONCLUSIONS: TGF-alpha and EGFR protein expression is increased early in head and neck squamous cell carcinogenesis and can be quantitated by computerized image analysis of immunohistochemical staining. Altered distribution of TGF-alpha protein in histologically normal mucosa from SCCHN patients compared with control mucosa from patients without cancer suggests a switch from a paracrine to an autocrine pathway.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8826952     DOI: 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  92 in total

1.  Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma.

Authors:  A Gabriella Wernicke; Adam P Dicker; Michal Whiton; Jana Ivanidze; Terry Hyslop; Elizabeth H Hammond; Arie Perry; David W Andrews; Lawrence Kenyon
Journal:  Radiat Oncol       Date:  2010-05-30       Impact factor: 3.481

2.  Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Authors:  K Kian Ang; Qiang Zhang; David I Rosenthal; Phuc Felix Nguyen-Tan; Eric J Sherman; Randal S Weber; James M Galvin; James A Bonner; Jonathan Harris; Adel K El-Naggar; Maura L Gillison; Richard C Jordan; Andre A Konski; Wade L Thorstad; Andy Trotti; Jonathan J Beitler; Adam S Garden; William J Spanos; Sue S Yom; Rita S Axelrod
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

3.  Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines.

Authors:  Kaisa Erjala; Misa Raitanen; Jarmo Kulmala; Reidar Grénman
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-05       Impact factor: 4.553

4.  Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.

Authors:  Mitchell J Frederick; Amy J VanMeter; Mayur A Gadhikar; Ying C Henderson; Hui Yao; Curtis C Pickering; Michelle D Williams; Adel K El-Naggar; Vlad Sandulache; Emily Tarco; Jeffrey N Myers; Gary L Clayman; Lance A Liotta; Emanuel F Petricoin; Valerie S Calvert; Valentina Fodale; Jing Wang; Randal S Weber
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 5.  Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.

Authors:  Juliette Thariat; Luka Milas; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

6.  Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF.

Authors:  Heewa Kareem; Karl Sandström; Ronny Elia; Lars Gedda; Matti Anniko; Hans Lundqvist; Marika Nestor
Journal:  Tumour Biol       Date:  2010-01-30

Review 7.  Head and neck cancer: an evolving treatment paradigm.

Authors:  David M Cognetti; Randal S Weber; Stephen Y Lai
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 8.  [Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy].

Authors:  T K Hoffmann; T L Whiteside; H Bier
Journal:  HNO       Date:  2005-03       Impact factor: 1.284

9.  Patterns of expressions of transforming growth factor and epidermal growth factor receptor in squamous cell lesions of the urinary bladder.

Authors:  M F Tungekar; J Linehan
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

10.  Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.

Authors:  Dong M Shin; Hongzheng Zhang; Nabil F Saba; Amy Y Chen; Sreenivas Nannapaneni; A R M Ruhul Amin; Susan Müller; Melinda Lewis; Gabriel Sica; Scott Kono; Johann C Brandes; William J Grist; Rachel Moreno-Williams; Jonathan J Beitler; Sufi M Thomas; Zhengjia Chen; Hyung Ju C Shin; Jennifer R Grandis; Fadlo R Khuri; Zhuo Georgia Chen
Journal:  Clin Cancer Res       Date:  2013-02-19       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.